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144 Poster Session IIcompared to the minor-mismatched pair. Conversely, when WT
HSC and TCs were transplanted into myeloablated and non-mye-
loablated mMTmice, BC engraftment was readily established, mak-
ing a direct anti-BC cytotoxicity unlikely as the sole cause of the BC
inhibition. FACS analysis of the bone marrow revealed a shift of the
developmental BC stages of from mature to immature stages in B
lymphopenic mice. While GVHD affected mice that received
WT grafts displayed a lower proportion of IgM expressing BCs, re-
cipients of mMTTCs showed a complete block in BC development
with an absent switch to the expression of IgM. In conclusion, TCs
from mMT mice can block BC maturation when transferred into
WTmice, an observation which shows that mature TC are capable
of interfering with BC regeneration post transplantation. This
HCT model using WT and mMT B6 mice provides a powerful
tool for studying the role of TC function in the process of donor
BC development post-HCT.396
B LYMPHOCYTE RECONSTITUTION FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS: CORRE-
LATION WITH PRE- AND POST-TRANSPLANT FACTORS
Richardson, D.S., Hodges, E., Mani, A., Hurlock, C., Newman, J.,
McKeag, N., Hill, K., Orchard, K.H. Southampton University Hospitals,
Southampton, Hampshire, United Kingdom.
We have performed a detailed analysis of the kinetics of B cell re-
constitution in patients who have undergone allogeneic stem cell
transplantation for haematological disorders. Whole blood samples
from 76 patients were analysed using monoclonal antibodies di-
rected against CD19, CD27 and IgD by multicolour flow cytome-
try. Total (CD191), naive (IgD1CD27-), IgD memory
(IgD1CD271) and class switched memory (IgD-CD271) B cell
populations were identified. Indications for transplantation were
haematological malignancy (n 5 74) and aplastic anaemia (n 5 2).
The stem cell source was from an unrelated donor in 29 cases or re-
lated/sibling donor in 47 cases. 39 patients received reduced inten-
sity and 37 full intensity transplant conditioning regimens. In vivo
T-cell depletion with Campath 1H was used for all patients with
a matched unrelated donor and those receiving reduced intensity
conditioning. The majority of patients (n5 57) have retained a pre-
dominantly naive B cell phenotype at 2 to 48 months (median 18.7
months). 7 patients have a normal percentage of memory B lympho-
cytes with a low percentage of class-switched B cells. 7 patients cur-
rently have a normal percentage of class-switched B cells. 8 patients
achieved normal class-switched B cell numbers but returned to a na-
ive B cell phenotype. In one patient this preceded relapse of under-
lying leukaemia and in two others was consequent on treatment
with chemotherapy or corticosteroid. Only one patient who re-
quired treatment with additional immunosuppressive therapy,
post transplant, subsequently achieved a normal percentage of
class-switched B cells. The use of Campath 1H, stem cell source
(marrow or peripheral blood), donor type (unrelated or related),
use of full or reduced intensity conditioning or the administration
of donor lymphocyte infusions post-transplant were not predictive
of development of a normal percentage of class-switched B lympho-
cytes. B cell immune reconstitution phenotype does not appear to
correlate with the incidence of chronic GvHD or in this cohort of
patients with current disease status. The timing of development of
a normal percentage of class-switched B cells cannot be reliably pre-
dicted in this patient population.397
MINIMAL RESIDUAL DISEASE AND CHIMERISM IN CML PATIENTS RE-
CEIVING ALLOGENEIC TRANSPLANTS AFTER MYELOABLATIVE OR RE-
DUCED CONDITIONING
Uzunel, M., Mattsson, J., Hauzenberger, D., Ringden, O. Karolinska
University Hospital, Stockholm, Sweden.
It is not known whether reduced conditioning is associated with
prolonged period of detectable disease after SCT in patients withCML. We have therefore compared BCR-ABL transcript levels in
patients receiving a conventional myeloablative conditioning with
those receiving reduced conditioning. We also made chimerism
studies in both patient groups.
Myeloablative Conditioning (MYC): 31 patients, 19 matched
unrelated donors (MUD) and 12 sibling donors (Sib). Median age
was 42 years (10–61). Conditioning with Bu1Cy (n 5 31). Twenty
of theMUDpatients were also given ATG. Seven patients have died
(6 GVHD, 1 Relapse). Median follow-up time: 56 months (10–99).
Reduced Intensity Conditioning (RIC): 24 patients, 13 MUD
and 11 Sib. Median age was 55 years (11–64). Conditioning with
Flu1Bu1ATG. Seven patients have died (3 Relapses, 1 GVHD,
3 other reasons). Median follow-up time: 43 months (18–100). Re-
sults: There was no statistical significant difference in overall sur-
vival and relapse free survival between both groups. 5/29 patients
in the MYC group relapsed as compared to 7/23 patients in the
RIC group. Only one patient in the RIC group rejected the graft.
The incidence of severe acute GVHD was significantly higher in
the MYC group (48%) as compared to the RIC group (13%), p 5
0.004. Interestingly, the incidence of chronic GVHD was slightly
higher in the RIC group, 51% vs. 37% (p 5 0.11).
During the first 3 months, MRD levels in the RIC group was in
median one log of magnitude higher than in the MYC group (p 5
0.01). After that, no significant differences in the MRD incidence
and MRD level were found between the groups.
Median time to complete donor T-cell chimerism was 34 days
(14–285) in the MYC group as compared to 60 days (24–245) in
the RIC group (p5 0.04). Also, complete myeloid cell engraftment
was delayed in the RIC group, median 44 days (14–165) as
compared to 25 days (14–270) in the MYC group (p 5 0.02).
Conclusion: Despite higher BCR-ABL levels during the early
post-transplant period and higher incidence of mixed chimerism,
nonmyeloablative transplantation for CML patients may induce
molecular remission in the majority of the patients.398
TRANSCRIPTIONAL ANALYSIS OF CD41 T CELLS FROM TOLERANT PA-
TIENTS AND NORMAL CONTROLS. GENE EXPRESSION IN PATIENTS DIF-
FERS FROM NORMAL CONTROLS
Tabellini, L., Haeusermann, P., Bumgarner, T.E., Flowers, M.E.,
Grogan, B.M., Martin, P.J., Hansen, J.A. Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
GVHD is a major complication of hematopoietic cells transplan-
tation (HCT). Immune suppression therapy (IST) is administered
for prophylaxis and treatment of GVHD. Chronic GVHD usually
occurs within 3 to 24 months from HCT, and requires on average
24 months of IST before disease becomes quiescent and IST can
be withdrawn. We have characterized gene expression changes in
CD41 T cells of HCT patients with resolved GVHD to see if dis-
tinct translational changes are associated with immunological toler-
ance. The study included 10 patients who had been off all IST for at
least 4 months (median 9 months; range 4–38 months) without ev-
idence of active cGVHD. Six achieved tolerance within the first year
(‘‘early’’ tolerance). Four developed cGVHD within the first year
but were subsequently withdrawn from all IST between 6–38
months post-HCT (‘‘late’’ tolerance). Blood samples from early tol-
erants were obtained between 12–29 (median 12) months, from the
late tolerants were obtained between 38–52 (median 45) months
post-HCT. CD41 T cells were isolated from cryopreserved
PBMC. RNA was hybridized on HumanRef-8 v2 BeadChips,
scanned and normalized using BeadStudio (Illumina), gene expres-
sion in CD41T cells from the 10 tolerant patients was compared to
gene expression in CD41 T cells from 19 normal controls using
a false positive discovery rate of \10. Expression levels differed
for 266 genes in tolerant patients (124 upregulated and 142 down-
regulated) compared to normal controls; and 189 of these genes
could be assigned to a functional class. Selected examples are:
DNA repair (6 genes); cell cycle regulation (18 genes); RNA tran-
scription (9 genes); protein translation (8 genes); ubiquitin cycle
(6 genes); glycolysis and aerobic respiration pathways (5 genes);
and lipid metabolism (3 genes). FAS gene showed relatively strong
upregulation in all patients. Although the numbers of early and late
